Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroko Shibata

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Journal of Biomedical Materials Research. Part A|July 1, 2004
Effective accumulation of poly(vinylpyrrolidone-co-vinyl laurate) into the spleenYasuo Yoshioka, Yasuo Tsutsumi, Yohei Mukai, et al.
Biological & Pharmaceutical Bulletin|February 3, 2007
Creation of novel cell-penetrating peptides for intracellular drug delivery using systematic phage display technology originated from Tat transduction domainHaruhiko Kamada, Takayuki Okamoto, Maki Kawamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic windowHiroko Shibata, Yasuo Yoshioka, Shinji Ikemizu, et al.
Scientific Reports|March 4, 2018
Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered FcγReceptor IIIa-Immobilized ColumnMasato Kiyoshi, Jose M M Caaveiro, Minoru Tada, et al.
Bioanalysis|April 5, 2019
Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory studyKazuko Nishimura, Hiroko Shibata, Muneo Aoyama, et al.
Journal of Pharmaceutical Sciences|January 14, 2020
Recent Achievements and Current Interests in Research on the Characterization and Quality Control of Biopharmaceuticals in JapanAkiko Ishii-Watabe, Hiroko Shibata, Hiroyuki Suetomo, et al.
Physiological Reports|June 4, 2017
Sodium balance, circadian BP rhythm, heart rate variability, and intrarenal renin-angiotensin-aldosterone and dopaminergic systems in acute phase of ARB therapyYukako Isobe-Sasaki, Michio Fukuda, Yoshiaki Ogiyama, et al.
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|July 31, 2022
[Investigation of Foreign Particles in Moderna COVID-19 Vaccine]Hiroko Shibata, Yusuke Nomura, Tsuyoshi Kawakami, et al.
Biochemical and Biophysical Research Communications|August 18, 2009
Novel protein engineering strategy for creating highly receptor-selective mutant TNFsTetsuya Nomura, Yasuhiro Abe, Haruhiko Kamada, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 29, 2009
Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis miceTetsuya Nomura, Yasuhiro Abe, Haruhiko Kamada, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Journal of Biomedical Materials Research. Part A|July 1, 2004
Effective accumulation of poly(vinylpyrrolidone-co-vinyl laurate) into the spleenYasuo Yoshioka, Yasuo Tsutsumi, Yohei Mukai, et al.
Biological & Pharmaceutical Bulletin|February 3, 2007
Creation of novel cell-penetrating peptides for intracellular drug delivery using systematic phage display technology originated from Tat transduction domainHaruhiko Kamada, Takayuki Okamoto, Maki Kawamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic windowHiroko Shibata, Yasuo Yoshioka, Shinji Ikemizu, et al.
Scientific Reports|March 4, 2018
Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered FcγReceptor IIIa-Immobilized ColumnMasato Kiyoshi, Jose M M Caaveiro, Minoru Tada, et al.
Bioanalysis|April 5, 2019
Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory studyKazuko Nishimura, Hiroko Shibata, Muneo Aoyama, et al.
Journal of Pharmaceutical Sciences|January 14, 2020
Recent Achievements and Current Interests in Research on the Characterization and Quality Control of Biopharmaceuticals in JapanAkiko Ishii-Watabe, Hiroko Shibata, Hiroyuki Suetomo, et al.
Physiological Reports|June 4, 2017
Sodium balance, circadian BP rhythm, heart rate variability, and intrarenal renin-angiotensin-aldosterone and dopaminergic systems in acute phase of ARB therapyYukako Isobe-Sasaki, Michio Fukuda, Yoshiaki Ogiyama, et al.
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|July 31, 2022
[Investigation of Foreign Particles in Moderna COVID-19 Vaccine]Hiroko Shibata, Yusuke Nomura, Tsuyoshi Kawakami, et al.
Biochemical and Biophysical Research Communications|August 18, 2009
Novel protein engineering strategy for creating highly receptor-selective mutant TNFsTetsuya Nomura, Yasuhiro Abe, Haruhiko Kamada, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 29, 2009
Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis miceTetsuya Nomura, Yasuhiro Abe, Haruhiko Kamada, et al.
Pageof 9